Abl Bio Inc.

Glaxosmithkline Intellectual Property Development Limited

I-mab Biopharma US Limited

I-mab

I-mab Biopharma (hangzhou) Co., Ltd.

Wenqing Jiang

Lei Fang

Zhengyi Wang

Bingshi Guo

Eunyoung Park

Qing Shan Zhang

Sang Hoon Lee

Alan Peter Lewis

Yongqiang Wang

Jingwu Zang

Yangsoon Lee

Radha Shah Parmar

Liuqing Yang

Eunsil Sung

Tejinder Kaur Bhinder

Yangsheng Qiu

Jaeho Jung

Yingli Ma

Guhan Nagappan

Yanjiao Zhou

Chong Ding

Weon-Kyoo You

Xu Feng

Byungje Sung

Hyejin Chung

Youngdon Pak

Yong-Gyu Son

Jiseon Yoo

Uijung Jung

Eunjung Kim

Minji Park

Hyoju Choi

YoungKwang Kim

Yeun Ju Kim

The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof

The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof

The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.

Anti-LAG-3 antibodies and uses thereof

Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof

The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.

Binding agonist for treatment of neurological and other disorders

Growing community of inventors

Shanghai, China

Wenqing Jiang